It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Primary vasopressor efficacy of epinephrine during cardiopulmonary resuscitation (CPR) is due to its α-adrenergic effects. However, epinephrine plays β1-adrenergic actions, which increasing myocardial oxygen consumption may lead to refractory ventricular fibrillation (VF) and poor outcome. Effects of a single dose of esmolol in addition to epinephrine during CPR were investigated in a porcine model of VF with an underlying acute myocardial infarction. VF was ischemically induced in 16 pigs and left untreated for 12 min. During CPR, animals were randomized to receive epinephrine (30 µg/kg) with either esmolol (0.5 mg/kg) or saline (control). Pigs were then observed up to 96 h. Coronary perfusion pressure increased during CPR in the esmolol group compared to control (47 ± 21 vs. 24 ± 10 mmHg at min 5, p < 0.05). In both groups, 7 animals were successfully resuscitated and 4 survived up to 96 h. No significant differences were observed between groups in the total number of defibrillations delivered prior to final resuscitation. Brain histology demonstrated reductions in cortical neuronal degeneration/necrosis (score 0.3 ± 0.5 vs. 1.3 ± 0.5, p < 0.05) and hippocampal microglial activation (6 ± 3 vs. 22 ± 4%, p < 0.01) in the esmolol group compared to control. Lower circulating levels of neuron specific enolase were measured in esmolol animals compared to controls (2[1–3] vs. 21[16–52] ng/mL, p < 0.01). In this preclinical model, β1-blockade during CPR did not facilitate VF termination but provided neuroprotection.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Istituto Di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy (GRID:grid.4527.4) (ISNI:0000000106678902)
2 University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822); Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Anesthesiology, Intensive Care and Emergency, Milan, Italy (GRID:grid.414818.0) (ISNI:0000 0004 1757 8749)
3 University of Milan, Dipartimento Di Medicina Veterinaria, Lodi, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822)
4 University of Milan, Dipartimento Di Medicina Veterinaria, Lodi, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822); Fondazione UniMi, Mouse and Animal Pathology Lab (MAPLab), Milan, Italy (GRID:grid.4708.b)
5 University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822)